VTRS · NASDAQ · STOCK
Viatris (VTRS) Stock Analysis
$17.66
52W $9.73 – $18.43
63/100
$20.54B
-49.0
0.86
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is VTRS Bullish or Bearish?
Bullish.
Innellis AI committee rates Viatris (VTRS) Buy with a composite score of 63/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.28 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.72 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.0x is a discount to asset value — Value
- Dividend yield of 5.1% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -2.8% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 16%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.0x is a discount to asset value
− ROE of only -2.8% -- cheap may mean cheap for a reason
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 33 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 62.7 to 62.7.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
57.7
Neutral
MACD Histogram
-0.022
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$15.89
Resistance
$18.33
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$17.56
Above
EMA 21
$17.39
Above
EMA 50
$17.06
Above
EMA 200
$15.34
Above
Fundamental Analysis
Valuation
100
Growth
87
Profitability
9
Financial Health
71
Cash Flow
70
Valuation
P/E Ratio
-49.0×
P/B Ratio
1.44×
PEG Ratio
-3.36
Dividend Yield
2.72%
52W High
$18.43
52W Low
$9.73
Quality & Growth
ROE
-2389.2%
ROA
-945.0%
Gross Margin
3483.1%
Operating Margin
-59.2%
Revenue Growth YoY
—
Debt / Equity
0.96
AI Fundamental Assessment
P/E ratio of -49.0 (inexpensive relative to a 15-40x range); Price-to-book of 1.4x; PEG ratio of -3.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -23.9%; Return on assets of -9.5%; Net margin of -2.8%; Gross margin of 34.8%; Current ratio of 1.58 (healthy short-term liquidity); Debt-to-equity of 0.96; Free cash flow per share is positive (1.61); Most recent quarter beat estimates by 12.6%; 5 consecutive earnings beats; EPS growth accelerating (+3.5% -> +16.9% QoQ); Average YoY EPS growth of 11.3%; Analyst estimates rising over recent quarters
Get the Full VTRS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →